SPAEN is delighted to provide a comprehensive report of the ASCO 2012 medical highlights in GIST and Sarcomas from Dr Axel Le Cesne, Gustave Roussy Institute, Villejuif (France). Sarcomas and GIST were presented at 5 plenary and parallel sessions. These were rich in terms of innovation and therapeutic concepts, reporting study results that may have an impact on our daily practice, whether in GIST or sarcomas.
Conducting clinical trials in people with rare cancers (incl. Sarcomas) is not easy when the number in a small trial do not add up to convincing evidence. Now some researchers are pressing for a new approach - using Bayesian trial designs to make the most of available knowledge. Read more at Cancer World.
Phase III Data on Regorafenib Met Primary Endpoint Showing Significant Improvement in Progression-Free Survival (PFS) in Patients with GIST
Bayer HealthCare announced on the 4th of June 2012 data from the Phase III GRID (GIST – Regorafenib In Progressive Disease) trial evaluating its investi-gational drug Regorafenib in patients with metastatic and/or unresectable (GIST) whose disease had progressed despite prior treatment with Imatinib (Glivec®) and Sunitinib (Sutent).
EORTC is currently conducting A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with Retroperitoneal sarcomas (RPS) - STRASS. SPAEN has developed a leaflet/article explaining the STRASS study in non-technical terms with the aim to help patients and carers understand what the study might be able to offer them. This summary is not part of the study information and is not intended to replace any of the study information which is part of the informed consent process.
Sarcomas are rare malignant tumors, with an overall incidence of 6/105/year. Bone and soft tissue connective tissue tumours encompass more than 50 different rare histotypes and more than 150 different molecular subtypes. The incidence of individual rare sarcomas subtypes is often less than 0.5/105/year. Given the rarity of sarcomas as a group, but even more as individual entities, few prospective clinical trials testing local or systemic treatments have been performed in specific subtypes of sarcomas. Clinical trials in specific histological and molecular subtypes of sarcoma can only be performed through integrated clinical networks, centres of clinical excellence, supported by translational analysis.
The campaign Rare Cancers Europe has been developed by ESMO in collaboration with major European stakeholders in rare cancers and rare diseases to address challenges and propose solutions to eliminate the hurdles that patients with rare cancers, researchers, medical professionals and the pharmaceutical industry working in this field face every day. Rare Cancers Europe (RCE) has been established as a partnership of cooperating organisations that work together to place the issue of rare cancers firmly on the European policy agenda, to identify and promote appropriate solutions and to exchange best practice. SPAEN has now been welcomed into the partnership initiative. http://www.rarecancerseurope.org
SPAEN regrets the released information from AB Science: “Masitinib significantly extends overall survival as second-line drug for GIST…”
On the 1st of February 2012 the “Global GIST Community” was confronted by a press release from a pharmaceutical company named AB Science to the financial media and a supporting Email “Late Breaking News” from the Life Raft Group (NJ, USA) to the GIST Patient Community. During the following days, leading GIST Experts and GIST Patient Groups around the world clearly expressed their concern about the content of this press release and manner of its delivery.